Journal
NATURE CHEMICAL BIOLOGY
Volume 6, Issue 8, Pages 595-601Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEMBIO.391
Keywords
-
Categories
Funding
- US National Institutes of Health [5P01CA92625, 5RO1GM084181]
- Burroughs Wellcome Career Award
- Ruth L. Kirschstein National Research Service Award [1F31CA144566]
- National Center for Research Resources at the US National Institutes of Health [RR-15301]
- US Department of Energy, Office of Basic Energy Sciences [DE-AC02-06CH11357]
Ask authors/readers for more resources
The development of selective inhibitors for discrete anti-apoptotic BCL-2 family proteins implicated in pathologic cell survival remains a formidable but pressing challenge. Such precisely tailored compounds would serve as molecular probes and targeted therapies to study and treat human diseases driven by specific anti-apoptotic blockades. In particular, MCL-1 has emerged as a major resistance factor in human cancer. By screening a library of stabilized alpha-helix of BCL-2 domains (SAHBs), we determined that the MCL-1 BH3 helix is itself a potent and exclusive MCL-1 inhibitor. X-ray crystallography and mutagenesis studies defined key binding and specificity determinants, including the capacity to harness the hydrocarbon staple to optimize affinity while preserving selectivity. MCL-1 SAHB directly targets MCL-1, neutralizes its inhibitory interaction with pro-apoptotic BAK and sensitizes cancer cells to caspase-dependent apoptosis. By leveraging nature's solution to ligand selectivity, we generated an MCL-1-specific agent that defines the structural and functional features of targeted MCL-1 inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available